Ground Swell Capital LLC Invests $1.03 Million in DexCom, Inc. (NASDAQ:DXCM)

Ground Swell Capital LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,283 shares of the medical device company's stock, valued at approximately $1,025,000. DexCom accounts for about 0.9% of Ground Swell Capital LLC's holdings, making the stock its 14th largest holding.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Canada Pension Plan Investment Board lifted its position in DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company's stock worth $75,471,000 after acquiring an additional 435,401 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock valued at $276,538,000 after purchasing an additional 353,019 shares during the period. Assenagon Asset Management S.A. grew its holdings in DexCom by 53.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company's stock valued at $66,352,000 after purchasing an additional 345,114 shares in the last quarter. Bellevue Group AG increased its stake in DexCom by 33.5% during the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company's stock worth $169,380,000 after buying an additional 306,604 shares during the period. Finally, Magnetar Financial LLC acquired a new position in DexCom in the 2nd quarter worth $31,793,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company's stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company's stock.

DexCom Stock Performance

Shares of DXCM stock traded down $0.65 during trading hours on Monday, reaching $69.70. The stock had a trading volume of 3,029,275 shares, compared to its average volume of 3,903,445. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a 50-day simple moving average of $69.85 and a 200-day simple moving average of $95.37. The firm has a market capitalization of $27.22 billion, a PE ratio of 41.74, a price-to-earnings-growth ratio of 2.16 and a beta of 1.17. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DXCM. Raymond James dropped their target price on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their target price on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Royal Bank of Canada dropped their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Finally, Baird R W downgraded shares of DexCom from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 26th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and an average price target of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.